BG104048A - Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион - Google Patents

Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион Download PDF

Info

Publication number
BG104048A
BG104048A BG104048A BG10404899A BG104048A BG 104048 A BG104048 A BG 104048A BG 104048 A BG104048 A BG 104048A BG 10404899 A BG10404899 A BG 10404899A BG 104048 A BG104048 A BG 104048A
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically acceptable
compound
composition
acceptable form
acceptable carrier
Prior art date
Application number
BG104048A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jai Patel
Hamish Ross
Jeffrey Granett
Robin Price
Paul WRAY
Original Assignee
Smithkline Beecham P.L.C.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithkline Beecham P.L.C.
Publication of BG104048A publication Critical patent/BG104048A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BG104048A 1997-06-05 1999-12-27 Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион BG104048A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
BG104048A true BG104048A (bg) 2000-07-31

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104048A BG104048A (bg) 1997-06-05 1999-12-27 Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион

Country Status (29)

Country Link
EP (1) EP0998284A1 (ja)
JP (1) JP2001521553A (ja)
KR (1) KR20010013410A (ja)
CN (3) CN1112926C (ja)
AP (1) AP1214A (ja)
AR (2) AR008198A1 (ja)
AU (1) AU8215098A (ja)
BG (1) BG104048A (ja)
BR (1) BR9810405A (ja)
CA (2) CA2333352A1 (ja)
CO (1) CO4940400A1 (ja)
DZ (1) DZ2510A1 (ja)
EA (1) EA002384B1 (ja)
GB (1) GB9711683D0 (ja)
HU (1) HUP0004070A3 (ja)
ID (1) ID24264A (ja)
IL (1) IL133074A0 (ja)
MX (1) MXPA99011322A (ja)
NO (2) NO995938L (ja)
NZ (2) NZ523725A (ja)
OA (1) OA11306A (ja)
PE (1) PE78899A1 (ja)
PL (1) PL337201A1 (ja)
SK (1) SK164899A3 (ja)
TR (2) TR199902963T2 (ja)
TW (1) TW570797B (ja)
UY (1) UY25032A1 (ja)
WO (1) WO1998055122A1 (ja)
ZA (2) ZA9811572B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
AR015120A1 (es) 2001-04-18
AR008198A1 (es) 1999-12-29
EP0998284A1 (en) 2000-05-10
CA2292629C (en) 2004-01-06
UY25032A1 (es) 1998-11-26
PL337201A1 (en) 2000-08-14
AU8215098A (en) 1998-12-21
NO20040738L (no) 2000-02-02
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
EA199901116A1 (ru) 2000-06-26
CN1526391A (zh) 2004-09-08
BR9810405A (pt) 2000-08-29
ZA9811572B (en) 1999-07-22
OA11306A (en) 2003-10-22
HUP0004070A2 (hu) 2002-02-28
CN1430959A (zh) 2003-07-23
TR200002790T2 (tr) 2001-11-21
NZ523725A (en) 2004-09-24
TR199902963T2 (xx) 2000-02-21
NZ513922A (en) 2001-09-28
CN1259050A (zh) 2000-07-05
CA2333352A1 (en) 1998-12-10
DZ2510A1 (fr) 2003-01-25
NO995938L (no) 2000-02-02
NO995938D0 (no) 1999-12-03
CN1112926C (zh) 2003-07-02
WO1998055122A1 (en) 1998-12-10
KR20010013410A (ko) 2001-02-26
ZA984826B (en) 1999-08-03
SK164899A3 (en) 2000-11-07
CA2292629A1 (en) 1998-12-10
MXPA99011322A (es) 2004-12-02
JP2001521553A (ja) 2001-11-06
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
ID24264A (id) 2000-07-13
IL133074A0 (en) 2001-03-19
PE78899A1 (es) 1999-10-22
AP1214A (en) 2003-10-08
EA002384B1 (ru) 2002-04-25
CO4940400A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
CZ298469B6 (cs) Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
BG104048A (bg) Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион
HRP20000405A2 (en) Hydrate of 5-/4-/2-(n-methyl-n-(2-pyridil)amino) ethoxy)benzyl/thiazolidine-2,4-dione, maleic acid salt
US20040082621A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
SK179399A3 (en) Use of insulin sensitiser and an insulin
BG64817B1 (bg) Комбинация от тиазолидиндион и сулфонилуреа, състав и използване
TW586926B (en) A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
CZ432299A3 (cs) Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
AU9513401A (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
CZ9904579A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
HU226960B1 (en) Combination of a dioxothiazolidine and metformin, and pharmaceutical compositions containing the same for the treatment of diabetes